| scholarly article | Q13442814 |
| P356 | DOI | 10.1188/10.CJON.771-783 |
| P953 | full work available at URL | http://ons.metapress.com/index/H782631737819463.pdf |
| P698 | PubMed publication ID | 21112854 |
| P2093 | author name string | Cathy Maxwell | |
| P2860 | cites work | Repeat motifs of tau bind to the insides of microtubules in the absence of taxol | Q24540276 |
| HER-2 gene amplification can be acquired as breast cancer progresses | Q24563115 | ||
| ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome | Q24657877 | ||
| Prospective identification of tumorigenic breast cancer cells | Q24683474 | ||
| Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status | Q27824865 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Gene expression profiling predicts clinical outcome of breast cancer | Q27860732 | ||
| Molecular portraits of human breast tumours | Q28032461 | ||
| Repeated observation of breast tumor subtypes in independent gene expression data sets | Q28131820 | ||
| The MINDACT trial: the first prospective clinical validation of a genomic tool | Q28242008 | ||
| A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer | Q28297827 | ||
| Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials | Q29547513 | ||
| Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors | Q29617042 | ||
| Circulating tumor cells, disease progression, and survival in metastatic breast cancer | Q29619276 | ||
| Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis | Q30004190 | ||
| American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer | Q33303529 | ||
| Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer | Q33852049 | ||
| Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer | Q34398320 | ||
| Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer | Q34496969 | ||
| Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer | Q34601123 | ||
| HER-2 and topoisomerase II as predictors of response to chemotherapy | Q34747499 | ||
| Commercialized multigene predictors of clinical outcome for breast cancer. | Q34783293 | ||
| Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome | Q34988317 | ||
| Molecular portraits and the family tree of cancer | Q35010198 | ||
| Tumor microenvironment of metastasis in human breast carcinoma: a potential prognostic marker linked to hematogenous dissemination | Q35165988 | ||
| Closing in on a breast cancer gene on chromosome 17q | Q35195396 | ||
| Therapeutic implications of cancer stem cells. | Q35756019 | ||
| Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer | Q36079736 | ||
| Relationship between estrogen receptor values and clinical data in predicting the response to endocrine therapy for patients with advanced breast cancer | Q36516136 | ||
| Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease | Q36615272 | ||
| DNA topoisomerase IIalpha expression and the response toprimary chemotherapy in breast cancer | Q36648223 | ||
| American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer | Q36678853 | ||
| Markers predicting clinical benefit in breast cancer from microtubule-targeting agents | Q37033609 | ||
| Development of the 21-gene assay and its application in clinical practice and clinical trials | Q37079600 | ||
| Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms | Q37124095 | ||
| Prognostic versus predictive value of biomarkers in oncology. | Q37131985 | ||
| Current status of prognostic profiling in breast cancer | Q37151603 | ||
| HER-2 positive breast cancer: what else beyond trastuzumab-based therapy? | Q37184721 | ||
| Breast cancer stem cells and tumor suppressor genes | Q37300676 | ||
| Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer | Q37352434 | ||
| Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy | Q37426293 | ||
| Prognosis of BRCA-associated breast cancer: a summary of evidence | Q37605624 | ||
| The counseling and management of young healthy BRCA mutation carriers | Q37613370 | ||
| Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer | Q39893964 | ||
| Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype | Q40281834 | ||
| Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer | Q41756399 | ||
| Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma | Q42466578 | ||
| Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade | Q42510471 | ||
| Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer | Q43964184 | ||
| Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer Databases | Q44438551 | ||
| Promising test flags BRCA mutations in populations of Hispanic women | Q45203626 | ||
| Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer | Q46201981 | ||
| Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity | Q46328432 | ||
| Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma | Q46448642 | ||
| Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer | Q46516617 | ||
| Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients | Q46580491 | ||
| A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer | Q46695982 | ||
| retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: | Q46761542 | ||
| Combination chemotherapy in the management of breast cancer metastases | Q48891328 | ||
| Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. | Q50709872 | ||
| Genomics. Beyond the book of life. | Q53502363 | ||
| The prognostic role of a gene signature from tumorigenic breast-cancer cells. | Q55042952 | ||
| HER2 and Response to Paclitaxel in Node-Positive Breast Cancer | Q57578418 | ||
| Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites | Q59567861 | ||
| Prognostic significance of serum c-erbB-2 protein in breast cancer patients | Q64019063 | ||
| Immunohistochemical detection of the neu protein in tissue sections of human breast tumors with amplified neu DNA | Q68137816 | ||
| Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study | Q68215560 | ||
| c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer | Q72673347 | ||
| Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study | Q73645071 | ||
| Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer | Q77924534 | ||
| Circulating tumor cells in breast cancer | Q80496864 | ||
| Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab | Q81151636 | ||
| Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma | Q81565196 | ||
| Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401 | Q83305244 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 771-783 | |
| P577 | publication date | 2010-12-01 | |
| P1433 | published in | Clinical Journal of Oncology Nursing | Q15756951 |
| P1476 | title | Biomarker research in breast cancer | |
| Biomarker Research in Breast Cancer | |||
| P478 | volume | 14 |
| Q34584855 | Biclustering reveals breast cancer tumour subgroups with common clinical features and improves prediction of disease recurrence | cites work | P2860 |
Search more.